---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-218062"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:34:56.396976+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apellis updates on 8 retinal vasculitis events with SYFOVRE; recommends switching to 18-gauge filter needle

## Summary
- Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.
- Last confirmed event on June 20; over 32,000 vials distributed since then with no new confirmed events.
- One additional occlusive event in May reported after July 29; all events occurred after first injection.
- Company recommends discontinuing use of 19-gauge filter needle kits; now exclusively distributing 18-gauge filter needle kits.
- Patient outcomes: 1 stable, 2 near baseline, 2 severe vision impairment, 3 pending; two suspected events also reported.

## SEC filing metadata
- accession: 0001193125-23-218062
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/0001193125-23-218062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/d539134d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-218062
- JSON: https://secwatch.observer/filing/0001193125-23-218062.json
- Plain text: https://secwatch.observer/filing/0001193125-23-218062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.